Androgen Deprivation Therapy (ADT) Market Revenue Growth
By Major Market Players Pfizer Inc., Astellas Pharma Inc.,
Johnson & Johnson, Novartis International AG, Veru Inc.,
Sanofi S.A., GlaxoSmithKline plc
Androgens are male sex hormones responsible for masculine characteristics such ad muscular
build, deeper voice, and facial hair. Most of the androgens are produced in testes and their two
most common types are dihydrotestosterone (DHT) and testosterone. Along with normal
functions, androgens also contribute to prostate cancer cell growth, especially during early
stages of the cancer. Androgen deprivation therapy, also called androgen suppression therapy, is
used either to reduce the production of androgens in the patient’s body or to modulate the way
androgens work, thus ultimately inhibiting growth of prostate cancer cells.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2559
Androgen Deprivation Therapy (ADT) Market Drivers
Key players in the market are focusing on research to develop new drugs and broaden the
indication label of current drugs for treatment of androgen deprivation therapy (ADT), which is
expected to boost the global androgen deprivation therapy (ADT) market growth over the
forecast period.
For instance, in February 2018, Janssen Pharmaceutica, a subsidiary of Johnson & Johnson
received approval for its drug ERLEADA (apalutamide) in treatment of non-metastatic castration-
resistant prostate cancer (CRPC). ERLEADA is a next-generation androgen receptor inhibitor,
which belongs to the class of drugs anti-androgens and blocks the effect of testosterone to slow
down the process of tumor growth and metastasis. It is the first U.S. Food and Drug
Administration (FDA) approved drug for the treatment of patients with non-metastatic CRPC.